Report : Middle East & Africa Immunodiagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product [Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others], Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)
At 8.2% CAGR, the MEA Immunodiagnostics Market is speculated to be worth US$ 927.14 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the MEA immunodiagnostics market was valued at US$ 591.94 million in 2022 and is expected to reach US$ 927.14 million by 2028, registering an annual growth rate of 7.8% from 2022 to 2028. Rising focus on R&D Investment and expansion by key players and technological advancements in the field of immunodiagnostics are the critical factors attributed to the MEA immunodiagnostics market expansion.
Research and development (R&D) has been the crucial part of the pharmaceutical business. It enables companies to develop new products with significant medical and commercial potential for various diagnostic applications. Due to the surging prevalence of infectious diseases, companies are investing and generating huge revenues for expansion activities. During the COVID-19 pandemic, Thermo Fisher Scientific Inc. witnessed a 48% increase in the sales of its specialty diagnostics segment (sub-segmented into clinical diagnostics, immunodiagnostics, microbiology, transplant diagnostics, and healthcare market channel) in 2020. The segmental revenue of the company further increased in 2021 due to higher demand and sales of immunodiagnostic products used in the treatment of COVID-19. Manufacturers have also made some key investments in the last few years. Cisco Systems, a global technology leader, invested US$ 225 million to combat the COVID-19 pandemic. This enabled the company to expand significantly and also encourage new players to enter the MEA immunodiagnostics market.
On the contrary, inadequate reimbursement scenario hurdles the growth of MEA immunodiagnostics market.
Based on product, the MEA immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassay (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held 55.1% market share in 2022, amassing US$ 326.35 million. It is projected to garner US$ 507.07 million by 2028 to expand at 7.6% CAGR during 2022–2028.
Based on clinical indication, the MEA immunodiagnostics market is segmented into infectious diseases, hepatitis+HIV, endocrinology, gastrointestinal, metabolics and others. The infectious diseases segment held 45.0% market share in 2022, amassing US$ 266.40 million. It is projected to garner US$ 430.64 million by 2028 to expand at 8.3% CAGR during 2022–2028.
Based on end user, the MEA immunodiagnostics market is segmented into hospitals, clinics, diagnostics laboratories, academic and research institutes, and others. The hospital segment held 43.3% market share in 2022, amassing US$ 256.58 million. It is projected to garner US$ 394.48 million by 2028 to expand at 7.4% CAGR during 2022–2028.
Based on country, the MEA immunodiagnostics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of MEA. Our regional analysis states that Saudi Arabia captured 34.0% market share in 2022. It was assessed at US$ 200.96 million in 2022 and is likely to hit US$ 309.20 million by 2028, exhibiting a CAGR of 7.4% during the forecast period.
Key players dominating the MEA immunodiagnostics market are Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; PerkinElmer Inc.; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthineers AG; Svar Life Science AB; and Thermo Fisher Scientific Inc among others.
- In 2021, Siemens Healthineers announced that Atellica VTLi Patient-Side Immunoassay Analyzer has obtained a CE mark. The Atellica VTLi analyzer provides lab standard, high-sensitivity cardiac troponin I (hs-cTnI) test results to clinicians in eight minutes using a patient's fingerstick blood sample. This has expedited the diagnosis of heart attack with Atellica VTLi Patient-Side Analyzer for industry first fingerstick high-sensitivity troponin I at Point-of-Care.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: email@example.com